Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease
Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III…
Assuring Patients That Family History Won’t Hold Them Back
Some patients may share their concerns or worries that “family history” or “genes” prevent them from meeting their…